Hytest Ltd.

Natalia N Tamm

Alexey G Katrukha

Olga V Kolosova

Vladimir L Filatov

Alexey V Kharitonov

Alexander B Postnikov

Tatiana I Smolyanova

Karina R Seferyan

Alexei G Katrukha

Alexander G Semenov

The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

Method for determining the risk of cardiovascular events using IGFBP fragments

The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.

Immunoassay kit for quantification of BNP and proBNP

Immunoassay for quantification of an unstable antigen selected from BNP and proBNP

Growing community of inventors

Moscow, Russia

Natalia N Tamm